You are here
Expert services for the evaluation of immunotherapies
What do all immunotherapies under development have in common?
Whether in preclinical or clinical stage, they all need a robust and reliable immune monitoring to characterize and track the immune response.
Monitoring the immune response in a regulatory compliant setting is our expertise. ABL team supports tens of preclinical and clinical studies to evaluate the safety and efficacy of monoclonal antibodies (MAbs), immune-checkpoint inhibitors (ICI), therapeutic vaccines, Antibody Drug conjugates (ADCs), Chimeric Antigen Receptor T cells (CAR-T cells) and other cell therapies.
With a global presence both in Europe and North America, ABL can support large multicentric clinical trials. From study design to regulatory reports, our team has a long experience in developing, optimizing and validating either cell-based assays or immuno-assays.
Using a large panel of validated and robust technologies such as multi-parametric flow cytometry, Luminex®, Quanterix®, ELISpot, or ELISA, ABL offers a fit-for-purpose approach to its customers and partners.
Your source of immune information
Characterizing and monitoring the immune status of patients during the development of drug candidates is critical for biopharmaceutical companies and regulatory agencies. Indeed, this information (1) sheds light on the mechanism of action of investigational drugs and their impact on the immune system and (2) helps identify drug-response biomarkers in terms of efficacy, safety and immunogenicity